2019
DOI: 10.4993/acrt.27.73
|View full text |Cite
|
Sign up to set email alerts
|

Application of gamma-delta T cells obtained by ascites filtration for immunotherapy against malignant refractory ascites

Abstract: Ovarian cancer often presents with carcinomatous ascites effusion. Cell-free and concentrated ascites reinfusion therapy (CART) provides a symptomatic treatment. The ascitic fluid contains a large number of lymphocytes including γδ T cells which are cytotoxic and used as effector cells in cancer immunotherapy. We collected ascites-infiltrating lymphocytes (AILs) from the ascitic fluid that was obtained for CART. We examined four patients with ovarian cancer and two patients with primary peritoneal cancer. Five… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…In cancer therapy, the combination of CART followed by chemotherapy is safe and could be a treatment option for malignant massive ascites [11,12]. In particular, CART contributes to the relief of symptoms in gynecological cancer patients, without infection and/or allergic reaction [13][14][15].…”
Section: Introductionmentioning
confidence: 99%
“…In cancer therapy, the combination of CART followed by chemotherapy is safe and could be a treatment option for malignant massive ascites [11,12]. In particular, CART contributes to the relief of symptoms in gynecological cancer patients, without infection and/or allergic reaction [13][14][15].…”
Section: Introductionmentioning
confidence: 99%